ClinicalTrials.gg
Not yet recruitingNCT07343570Updated Jan 15, 2026

Comparison of Quadratus Lumborum and Combined Groin Nerve Blocks for Postoperative Analgesia After Open Inguinal Hernia Repair.

A Phase 3 interventional study of Ultrasound-guided lateral quadratus lumborum block and Combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block in Postoperative Analgesia of Inguinal Hernia Repair in Adults, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Al-Azhar University · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernia, Inguinal with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Hernia, Inguinal · Egypt.

Planned enrollment
16th of 43
66 · median 60
Started
2026
with 5 others
Phase 3
Only one
of the 45
Primary completion
2026-11
later than 12 of 16 live
Registered
35th of 45
by date
Lead sponsor
4 of 45
Al-Azhar University

Among the 45 studies in Hernia, Inguinal with a site in Egypt, this one is the 16th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2026, is the only one in phase 3, reaches primary completion later than 12 of the 16 other live ones, and was the 35th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

16 of the 45 studies in Hernia, Inguinal with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernia, Inguinal with a site in Egypt, or all of them as a file.
02

Study summary

This double-blind randomized controlled trial aimes to compares two ultrasound-guided regional techniques-lateral quadratus lumborum block versus combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block-for postoperative analgesia after elective unilateral open inguinal hernia repair under spinal anesthesia in adults.

03

Conditions studied

  • Postoperative Analgesia of Inguinal Hernia Repair in Adults

Browse trials for

Keywords

  • Quadratus lumborum [QL] block
  • Ilioinguinal-iliohypogastric (IIIH) nerve block
  • Genitofemoral block
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-75 years.
  • I-III.
  • Scheduled for elective unilateral open inguinal hernia repair under standardized spinal anesthesia.
  • Able to understand and use the Visual Analogue Scale (VAS).
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics.
  • Coagulopathy or current use of anticoagulants contraindicating peripheral nerve blocks.
  • Infection at the injection site.
  • Chronic opioid use (daily opioids >2 weeks) or chronic pain syndromes.
  • (BMI) >40 kg/m².
  • Conversion to other surgery or bilateral repair.
  • Pregnant patients.
  • Refusal to sign .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    Group 1 (Quadratus lumborum block)

    Ultrasound-guided lateral quadratus lumborum block. Local anesthetic: 30 ml of (Ropivacaine 0.2%) is injected at the appropriate fascial level.

    Procedure: Ultrasound-guided lateral quadratus lumborum block

  • Active comparator
    Group 2 ( Ilio-inguinal and ilio-hypogastric block)

    Ultrasound-guided ilio-inguinal and ilio-hypogastric block. Local anesthesia: 20 ml of 0.2% ropivacaine for ilio-inguinal and ilio-hypogastric block + 10 ml of 0.2% ropivacaine for genitofemoral anaesthesia, total injection volume = 30 ml.

    Procedure: Combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block

Interventions

  • ProcedureUltrasound-guided lateral quadratus lumborum block

    Ultrasound-guided lateral quadratus lumborum block. Local anesthetic: 30 ml of (Ropivacaine 0.2%) is injected at the appropriate fascial level.

  • ProcedureCombined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block

    Ultrasound-guided ilio-inguinal and ilio-hypogastric block. Local anesthesia: 20 ml of 0.2% ropivacaine for ilio-inguinal and ilio-hypogastric block + 10 ml of 0.2% ropivacaine for genitofemoral anaesthesia, total injection volume = 30 ml.

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption in the first 24 hours postoperatively

    Measures the total amount of opioid analgesics (expressed as morphine milligram equivalents, MME) consumed during the first postoperative 24 hours. It reflects overall analgesic efficacy of the two block techniques.

    Time frame: 24 hours after surgery.

Secondary outcomes

  1. Pain intensity (VAS pain scores at rest )

    Assesses the level of postoperative pain at rest using the Visual Analogue Scale (VAS), where 0 = no pain and 10 = worst imaginable pain.

    Time frame: 24 hours postoperatively.

  2. Pain intensity (VAS pain scores at movement)

    Assesses the level of postoperative pain during movement using the Visual Analogue Scale (VAS), where 0 = no pain and 10 = worst imaginable pain.

    Time frame: 24 hours postoperatively.

  3. Time to first analgesic request

    Determines the duration of effective analgesia provided by each block, defined as the interval from completion of the block to the first patient request for additional analgesia.

    Time frame: 24 hours.

  4. Proportion of patients requiring rescue opioid analgesia

    Percentage of patients who required additional opioid analgesics beyond the planned postoperative regimen, indicating inadequate analgesia from the primary block.

    Time frame: 24 hours.

  5. Incidence of postoperative block-related complications

    Evaluates safety of the blocks by recording complications such as hematoma, local anesthetic toxicity, or impaired mobility.

    Time frame: 24 hours.

  6. Patient satisfaction score

    Patient satisfaction with postoperative pain control will be evaluated using a 5-point Likert scale, allowing a simple yet reliable measure of the patient's overall analgesic experience. Each participant will rate their satisfaction as follows: 1 for "very dissatisfied," indicating poor pain relief and marked discomfort; 2 for "dissatisfied," reflecting inadequate but tolerable pain control; 3 for "neutral," representing acceptable analgesia without a clear sense of satisfaction; 4 for "satisfied," denoting good pain relief and minimal discomfort; and 5 for "very satisfied," corresponding to excellent pain control and full contentment with the postoperative analgesia regimen.

    Time frame: Assessed at 24 hours postoperatively.

  7. Post-anesthesia care unit (PACU) stay duration

    Measures the time spent in the PACU

    Time frame: 24 hours

  8. Total hospital stay duration

    Measures total length of hospital stay.

    Time frame: 24 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data can be shared upon a reasonable request from the corresponding author

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Nov 2026, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 15, 2026
StartEst.
Jan 28, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07343570
Collaborators
Benha University
Responsible party
Neveen Abd El Maksoad Kohaf (Lecturer of Clinical Pharmacy, Al-Azhar University) — Principal investigator
First posted
Jan 15, 2026
Start date
Jan 28, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

Neveen A. Kohaf, Ph.D
Contact
nevenabdo@azhar.edu.eg
01060383012

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion